Insilico Medicine Posts First Profitable Half-Year as AI-Designed Drug Enters Phase III
The intersection of artificial intelligence and biotechnology has reached a significant milestone in both commercial and clinical applications. Insilico Medicine, a prominent AI-driven drug discovery company headquartered in Hong Kong, has announced its first-ever profitable half-year.